Apratoxin A vs Kahalalide F
Head-to-head comparison of Apratoxin A (Apratoxin A) and Kahalalide F (Kahalalide F) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | Apratoxin A | Kahalalide F |
|---|---|---|
| Category | Experimental | Experimental |
| Full Name | Apratoxin A | Kahalalide F |
| Molecular Weight | N/A | 1111.3 Da |
| Half-Life | N/A | N/A |
| Amino Acids | N/A | N/A |
| Typical Dose | N/A in humans; nanomolar in vitro | 0.1-3 mg/m2 IV in early trials |
| Route | Intraperitoneal / Intravenous (preclinical) | Intravenous |
| Purity | ≥98% | ≥98% |
| Studies Count | 140 | 85 |
| Research Status | Pre-clinical | Pre-clinical |
Apratoxin A Benefits
- ✓antineoplastic
- ✓anti-angiogenic
- ✓Sec61 inhibition
- ✓anti-proliferative
Kahalalide F Benefits
- ✓antineoplastic
- ✓pro-apoptotic
- ✓membrane-active
- ✓anti-proliferative
Apratoxin A Dosing
preclinical in vitro nanomolar use|animal studies only|no human dosing established
Kahalalide F Dosing
IV infusion in phase I oncology studies|dose escalation used in trials|preclinical nanomolar assays
Apratoxin A Side Effects
- ⚠hepatotoxicity
- ⚠general cytotoxicity
- ⚠GI toxicity
Kahalalide F Side Effects
- ⚠fatigue
- ⚠nausea
- ⚠transaminase elevation
Research Overview
Apratoxin A
Apratoxin A is a well-studied lead compound for targeting secretory and membrane protein biogenesis in cancer cells. Medicinal chemistry programs around apratoxins focus on improving selectivity and reducing hepatotoxicity while preserving potency.
Kahalalide F
Kahalalide F was investigated in multiple preclinical and early clinical cancer studies because of its unusual membrane-disrupting and anti-tumor effects. Development highlighted the promise and limits of marine depsipeptides as oncology leads.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.